News
Fresenius has entered into a global licensing agreement for the commercialisation of Polpharma vedolizumab biosimilar candidate PB016.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback